Journal of Cell Science, Vol 110, Issue 3 337-343, Copyright © 1997 by Company of Biologists

JOURNAL ARTICLES

Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action

C Perez, NE Vilaboa, L Garcia-Bermejo, E de Blas, AM Creighton and P Aller
Centro de Investigaciones Biologicas, CSIC, Madrid, Spain.

We have compared the action on U-937 human promonocytic leukemia cells of two DNA topoisomerase II inhibitors, namely the epipodophyllotoxin etoposide and the bisdioxopiperazine ICRF-193. One hour pulse-treatment with 3 microM etoposide caused topoisomerase associated, primary DNA breakage, which was rapidly followed by apoptosis. By contrast, these effects were not observed upon pulse-treatment with 6 microM ICRF-193. However, continuous treatments with subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) produced several similar effects, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation. Under these conditions, etoposide produced a biphasic activation of protein kinase C, which consisted in an early transient activation (from hours 1 to 6) of the membrane-bound enzyme followed by a later activation (hour 48) of the total, membrane-bound and cytosolic enzyme. By contrast, ICRF-193 only provoked a late activation (from hours 72 to 96) of the total enzyme. When used at differentiation-inducing concentrations, both topoisomerase inhibitors caused a great stimulation of AP-1 binding activity, with maximum value at hour 12 in etoposide-treated cells and at hour 48 in ICRF-193-treated cells. By contrast, the binding activity of the NF-kappa(B) and EGR-1 transcription factors was little affected. It is concluded that topoisomerase II inhibitors may induce the differentiation of promonocytic cells, independently of their capacity to cause DNA strand breaks. However, there are other effects, such as the early activation of protein kinase C, which are probably derived from the production of primary DNA breakage by some anti-topoisomerase drugs.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. B. Hasinoff, M. E. Abram, N. Barnabé, T. Khélifa, W. P. Allan, and J. C. Yalowich The Catalytic DNA Topoisomerase II Inhibitor Dexrazoxane (ICRF-187) Induces Differentiation and Apoptosis in Human Leukemia K562 Cells Mol. Pharmacol., March 1, 2001; 59(3): 453 - 461. [Abstract] [Full Text]

				B. B. Hasinoff, M. E. Abram, G.-L. Chee, E. Huebner, E. H. Byard, N. Barnabé, V. J. Ferrans, Z.-X. Yu, and J. C. Yalowich The Catalytic DNA Topoisomerase II Inhibitor Dexrazoxane (ICRF-187) Induces Endopolyploidy in Chinese Hamster Ovary Cells J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 474 - 483. [Abstract] [Full Text]

				D. M. Zisterer, G. Campiani, V. Nacci, and D. C. Williams Pyrrolo-1,5-benzoxazepines Induce Apoptosis in HL-60, Jurkat, and Hut-78 Cells: A New Class of Apoptotic Agents J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 48 - 59. [Abstract] [Full Text]

				K. Riesbeck, A. Forsgren, A. Henriksson, and A. Bredberg Ciprofloxacin Induces an Immunomodulatory Stress Response in Human T Lymphocytes Antimicrob. Agents Chemother., August 1, 1998; 42(8): 1923 - 1930. [Abstract] [Full Text]

				L Garcia-Bermejo, C Perez, N. Vilaboa, E de Blas, and P Aller cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells J. Cell Sci., January 3, 1998; 111(5): 637 - 644. [Abstract] [PDF]

				K. Tsutsui, K. Tsutsui, K. Sano, A. Kikuchi, and A. Tokunaga Involvement of DNA Topoisomerase IIbeta in Neuronal Differentiation J. Biol. Chem., February 16, 2001; 276(8): 5769 - 5778. [Abstract] [Full Text] [PDF]